129 related articles for article (PubMed ID: 33896831)
1. Identification of novel autoantibodies in ascites of relapsed paclitaxel-resistant gastric cancer with peritoneal metastasis using immunome protein microarrays and proteomics.
Yang Z; Yan C; Liu W; Xu W; Li C; Yan M; Liu B; Zhu Z
Cancer Biomark; 2021; 31(4):329-338. PubMed ID: 33896831
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of CDH11 Promotes Metastasis and Resistance to Paclitaxel in Gastric Cancer Cells.
Yang Z; Yan C; Yu Z; He C; Li J; Li C; Yan M; Liu B; Wu Y; Zhu Z
J Cancer; 2021; 12(1):65-75. PubMed ID: 33391403
[No Abstract] [Full Text] [Related]
3. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
5. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
Arai H; Inoue E; Yamaguchi K; Boku N; Hara H; Nishina T; Tsuda M; Shitara K; Shinozaki K; Nakamura S; Hyodo I; Muro K; Sasako M; Terashima M; Nakajima TE
Cancer Med; 2021 Nov; 10(21):7673-7682. PubMed ID: 34655175
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
10. [A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Iwai N; Wakabayashi N; Matsumoto N; Morita Y; Tanaka N; Yoriki H; Fujii K; Takada R; Takaya H; Masuzawa A; Takami S; Kataoka K
Gan To Kagaku Ryoho; 2015 Mar; 42(3):351-4. PubMed ID: 25812506
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
14. Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.
Makinoya M; Miyatani K; Matsumi Y; Sakano Y; Shimizu S; Shishido Y; Hanaki T; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Saito H; Nakayama Y; Osaki M; Okada F; Fujiwara Y
Sci Rep; 2024 May; 14(1):10075. PubMed ID: 38698201
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Emoto S; Kitayama J; Ishigami H; Yamaguchi H; Watanabe T
Ann Surg Oncol; 2015 Mar; 22(3):780-6. PubMed ID: 25216603
[TBL] [Abstract][Full Text] [Related]
17. Comparative proteomic analysis of human malignant ascitic fluids for the development of gastric cancer biomarkers.
Jin J; Son M; Kim H; Kim H; Kong SH; Kim HK; Kim Y; Han D
Clin Biochem; 2018 Jun; 56():55-61. PubMed ID: 29654727
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance and practice points of conversion therapy for gastric cancer with peritoneal metastasis].
Zhu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1094-1098. PubMed ID: 29130218
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Hidemura A; Kato M; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Nagawa H
Ann Oncol; 2010 Jan; 21(1):67-70. PubMed ID: 19605503
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
Kurita N; Shimada M; Iwata T; Nishioka M; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Nakao T
J Med Invest; 2011 Feb; 58(1-2):134-9. PubMed ID: 21372498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
